TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
- Resource Type
- Article
- Source
- In
Annals of Oncology April 2020 31(4):507-516 - Subject
Early drug development - Language
- ISSN
- 0923-7534